Pharmacological Inhibition of Brain EGFR Activation By a BBB-penetrating Inhibitor, AZD3759, Attenuates α-synuclein Pathology in a Mouse Model of α-Synuclein Propagation
Omid Tavassoly, Esther del Cid‐Pellitero, Frédérique Larroquette, Eddie Cai, Rhalena A. Thomas, Vincent Soubannier, Wen Luo, Thomas M. Durcan, Edward A. Fon
Topics & Concepts
Substantia nigraAlpha-synucleinNeuroscienceDopamineStriatumParkinson's diseaseNeurologyNeuronPathologyAmyloid (mycology)ChemistryBiologyDopaminergicMedicineDiseaseParkinson's Disease Mechanisms and TreatmentsAlzheimer's disease research and treatmentsNeurological diseases and metabolism